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Introduction
The proper management of potential occult lymph node
metastasis in thyroid cancer remains a matter of controversy.
Those who choose elective lymph node dissection insist that
metastasis is found in 50% to 80% of patients with clinically
negative lymph nodes, and that their removal reduces
recurrence.1 Opponents of this approach, while recognizing
that metastasis may be present, maintain that routine dissection
is unnecessary because the recurrence rate is only 1.4% and the
5-year mortality rate ranges from 0.9% to 17%.2
Most studies have shown that lymph node metastasis by
thyroid cancer is not associated with increased mortality,3 but
others have found a statistically significant association between
nodal metastasis and mortality in follicular cancer.4,5 The
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effect of nodal metastasis on survival may often be outweighed
by the benefits of age. When matched for age, the outcome of
patients with nodal metastases was found to be significantly
worse than that of patients who were nodal metastasis-free:
15% versus 41% among patients older than 40 years.6 When
controlled for other risk factors, such as older age and vascular
invasion, several large retrospective studies have shown that
lymph node metastasis is associated with an overall lower
survival rate,5,7,8 and this has led to the recommendation of
elective lymph node dissection in well-differentiated thyroid
cancer as a means of decreasing the recurrence rate
and improving survival.7 Although regional lymph node
metastasis is associated with a mortality rate of 78% in high-
risk groups,9 lymphadenectomy has only been shown to have
a significant benefit on the 20-year survival rate of the high-
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OBJECTIVES: To determine the feasibility of sentinel lymph node biopsy as a means of evaluating the cervical
lymph nodes of patients with papillary thyroid cancer.
METHODS: Isosulfan blue dye was injected around the tumour of 68 patients with papillary thyroid cancer;
sentinel lymph node biopsy was performed in addition to subtotal thyroidectomy and central and modified
lateral neck lymph node dissections. Surgical specimens were examined by routine processing to determine
whether metastasis was present.
RESULTS: Sentinel lymph nodes were identified in 63 (92.6%) of the 68 patients. There was concordance between
the sentinel lymph node status and the final regional lymph node status in 58 (92.1%) of the 63 patients. There
were five false-negative cases. Sentinel lymph node biopsy had a sensitivity of 87.5% (35/40), specificity of 100%
(23/23), positive predictive value of 100% (35/35), negative predictive value of 82.1% (23/28), and accuracy of
92.1% (58/63).
CONCLUSIONS: Sentinel lymph node biopsy may allow discrimination between patients with true lymph-
node-negative papillary thyroid carcinoma and those with non-palpable metastatic lymph nodes. It may also be
helpful in diagnosing metastases and avoiding unnecessary lymph node dissection in thyroid cancer. [Asian J Surg
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risk subgroup of patients with papillary thyroid cancer.10
The first lymph node that drains a primary tumour is
referred to as the sentinel lymph node (SLN), and if lymphatic
drainage occurs in a step-wise fashion, the SLN should reflect
the pathological status of the remaining lymph node
compartment. Routine adoption of prophylactic lymph node
dissection is therefore not generally accepted as standard
treatment for clinically occult nodal disease. The objectives of
this study were to determine whether SLN biopsy (SLNB) in
patients with papillary thyroid carcinoma is capable of
discriminating true lymph-node-negative patients from those
with non-palpable metastatic lymph nodes and whether SLNB
could provide an alternative to elective lymph node dissection
in patients with clinically occult lymph node metastasis.
Patients and methods
All patients with a preoperative diagnosis of papillary thyroid
carcinoma by fine needle aspiration were eligible for the
study. Exclusion criteria were cervical lymphadenopathy,
complications of chronic thyroiditis or Graves’ disease, and a
previous history of neck surgery or irradiation. This study was
approved by the University Ethics Board, and informed consent
was obtained from all patients.
At surgery, the thyroid nodule was exposed by laterally
retracting the sternohyoid muscle. A 27-gauge tuberculin
syringe was used to inject 0.3 mL of isosulfan blue
(Lymphazurin 1%, United States Surgical Corporation,
Norwalk, CT, USA) at the 3 o’clock, 6 o’clock, 9 o’clock and 12
o’clock positions. The lymph node that stained first was
presumed to be the SLN (Figure), and the blue lymphatic
channels were traced to the central compartment and the
lateral compartment. The SLN was sent to the pathology
laboratory for preparation of both frozen and permanent
sections. Several of the permanent sections from each SLN
were stained with haematoxylin and eosin in the usual manner.
Immunohistochemistry was not used in the assessment of the
lymph nodes. Total lobectomy and partial resection of the
contralateral lobe, so-called “subtotal thyroidectomy”, was
then performed, and central and modified ipsilateral lymph
node dissections were routinely performed.
Results
A total of 68 patients were enlisted (60 females, 8 males; age
range, 22–69 years; mean age, 42 years). Their primary tumours
ranged between 0.6 cm and 3.9 cm (mean, 1.9 cm) in maximum
diameter. All patients had a solitary palpable tumour and no
palpable cervical lymphadenopathy before surgery.
SLNs were identified in 63 of the 68 patients (92.6%). An
SLN was found in the central compartment in 59 of the 63
patients, in the lateral compartment in eight patients, and
four patients had an SLN in both compartments according to
the Classification of Thyroid Cancer, edited by the Japanese
Society of Thyroid Surgery.11 The mean number of SLNs
identified was 2.02 ± 3.41. Some of the parathyroid glands
were identified prior to the injection of isosulfan blue, but
others were easily identified because they stained blue.
Thirty-five of the 63 patients (55.6%) had metastasis-
positive SLNs, and 28 (44.4%) had metastasis-negative SLNs
(Table). There was concordance between the SLN status and
the final regional lymph node status in 58 of the 63 patients
(92.1%). Five of the 63 patients had metastasis-negative SLNs
but metastasis-positive regional lymph nodes. SLNB had
87.5% (35/40) sensitivity, 100% (23/23) specificity, 100%
(35/35) positive predictive value, 82.1% (23/28) negative
predictive value, and 92.1% (58/63) accuracy. There were no
operative complications and no complications with the use of
isosulfan blue.
Unlike some reports from Western countries, we had five
false-negative cases. The false-negative rate for thyroid cancer
in the West is unknown as modified neck dissection is not
performed in every case.
Discussion
Lymph node metastases from well-differentiated thyroid
cancers are associated with high regional recurrence rates.
Surgical options consist of blind nodal sampling, “berry
Figure. Isosulfan blue-stained sentinel lymph node (arrows) in the
central compartment.
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node status in 19 of 21 patients with papillary thyroid
cancer.18 In two patients, the SLN was negative for metastasis,
but the non-SLNs were positive. Their overall reliability rate of
SLNB was 86%, so it was a good technique for estimating the
status of cervical lymph nodes in patients with papillary thyroid
carcinoma.
Scintigraphic localization of SLNs has been attempted in
patients suspected of having thyroid cancer.19 On the day of
surgery, a technetium colloid was injected into the tumour.
During surgery, the primary tumour was excised first, and
then the SLNs were removed using a gamma probe. SLNs were
detected in patients with papillary thyroid cancer, and there
were no false-negative findings. Catarci et al used preoperative
lymphoscintigraphy with 99mTc-labelled colloidal albumin,
vital dye staining, and hand-held gamma probing in six patients
diagnosed with papillary thyroid cancer.20 They identified the
SLN by these methods in all six cases (100%), with identification
rates by preoperative lymphoscintigraphy, vital dye, and probe
scanning of 66%, 50% and 83%, respectively.
The malignancy of Hürthle cell tumours of the thyroid is
difficult to determine even during the final pathological
examination, and nodal metastasis of Hürthle cell tumours
has been described as a major indicator of mortality and
morbidity.21 SLNB may assist in the diagnosis of the
malignancy of Hürthle cell tumours or atypical follicular
tumours when there is no or questionable evidence of capsular
or vascular invasion on frozen sections. If metastasis is
identified in the sentinel node, then invasion can be presumed
and total thyroidectomy performed, thereby avoiding a second
operation.14
One of the benefits of SLN dissection may be the
identification of SLNs outside the central neck that contain
occult metastases of medullary thyroid carcinoma.14 This
would identify disease that would have been left unresected by
central neck dissection alone, and provide a more logical
approach to lateral neck dissection. SLN dissection may be
superior to jugular node sampling in detecting residual nodal
metastatic disease.
Although it continues to be a matter of controversy,
131I ablation has been shown by some authors to decrease local
recurrence and improve survival.5 The efficacy of 131I on sur-
vival of well-differentiated thyroid cancer has recently been
questioned.22 The selection of patients with metastatic disease
would allow a more directed approach of 131I ablation
postoperatively and possibly help resolve this controversy.
SLN sampling could be used to avoid 131I ablation in patients
with low-risk thyroid cancer whose SLN is negative.
picking” procedures, elective lymph node dissection, and
modified neck dissections.12 SLNB was developed as an
alternative to elective lymph node dissection for patients with
clinically occult lymph node metastasis.
Kelemen et al described the first use of SLNB for thyroid
carcinoma.13 These authors identified SLNs in 12 of 12 patients
with thyroid cancer; five SLNs were positive for thyroid
carcinoma. Central neck dissection alone was performed in
these five patients, and the SLN was the only tumour-bearing
lymph node in two of the cases. Haigh and Giuliano performed
SLNB in 17 thyroid cancers.14 One SLN failed to show
metastasis, but metastases were identified in nine (56%) of the
remaining 16 patients. However, as central neck dissections
were not performed after SLNB in all of the patients in these
two studies, the false-negative rate is unknown.
Complete central neck dissection should be performed in
patients whose lymph nodes are negative, as well as in patients
whose lymph nodes are positive. Dixon et al reported identifying
SLNs in 10 of 12 patients with papillary cancer;15 six had true-
positive SLNs, two had true-negative SLNs, and two had false-
negative SLNs (according to the results of node dissection in
one case and of lateral uptake on 131I scanning in the other).
Pelizzo et al identified SLNs in 22 of 29 patients, and detected
neoplastic involvement in four of the 22 cases.16 Among the
18 patients whose SLNs were not metastatic, the other nodes
were also disease-free. In two of the seven patients in whom
SLNs were not identified by the staining procedure, metastatic
nodes were detected in the central compartment. The authors
performed total thyroidectomy and lymph node dissection of
the central and lateral compartments in all of the 29 patients.
Arch-Ferrer et al identified SLNs in 20 of 22 patients with
papillary thyroid carcinoma,17 and the SLNs were positive in
12 of the 20 patients. Immunohistochemical analysis for CK-
7 revealed micrometastases in five of the eight SLNs previously
evaluated as negative by haematoxylin and eosin staining. One
of the two patients in whom an SLN could not be identified
had lymph node metastasis in the lateral compartment
and the other was metastasis-free. Fukui et al reported a
concordance between the SLN findings and the regional lymph
Table. Pathological diagnosis of sentinel and regional lymph nodes
Regional lymph node metastases
Positive Negative
n (%) n (%)
Positive 35 (55.6) –
Negative 5 (7.9) 23 (36.5)
Sentinel lymph
node metastases
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We had three patients in whom an SLN was detected in the
lateral compartment alone. Since our search for the SLN was
only successful when the surgeon proceeded from the central
compartment to explore the lateral compartment, it would
seem that for mapping purposes, exploration should not be
restricted to the lymph nodes of the central compartment.16
As some SLNs are located outside the central compartment of
the neck, SLNB for thyroid cancer must be performed outside
the central compartment. The combination of vital dye staining
and radiolymphoscintigraphy in thyroid cancer has increased
the yield of SLNB. The advantage of lymphoscintigraphy with
intraoperative gamma probe guidance is that the radiolabelled
material is injected preoperatively, thereby eliminating
disruption of the lymphatics during the initial dissection.
Radioscintigraphy also allows for the diagnosis and
identification of SLNs in patients whose SLN lies outside the
central compartment. SLNB with intraoperative gamma
probing is currently performed in our department.
Conclusion
The preliminary findings indicate that the SLN hypothesis
may be applicable to thyroid cancer. SLNB may allow
discrimination of true lymph-node-negative papillary thyroid
carcinoma patients from those with non-palpable lymph nodes.
It may also be helpful in diagnosing metastases and avoiding
unnecessary lymph node dissection in thyroid cancer. Selective
lymph node dissection not only lessens the chance of
locoregional relapse but also the number of complications.
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